These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8993604)

  • 41. Inhibition of liver glutathione S-transferase activity in rats by hypolipidemic drugs related or unrelated to clofibrate.
    Foliot A; Touchard D; Mallet L
    Biochem Pharmacol; 1986 May; 35(10):1685-90. PubMed ID: 3707598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug.
    Reddy JK; Reddy MK; Usman MI; Lalwani ND; Rao MS
    Environ Health Perspect; 1986 Mar; 65():317-27. PubMed ID: 3709457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alteration of rat liver endoplasmic reticulum Ca(2+)-ATPase thiol integrity by ciprofibrate, a peroxisome proliferator.
    Bennett AM; Williams GM
    Biochem Pharmacol; 1993 May; 45(10):2093-8. PubMed ID: 8512590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of LY171883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver.
    Cannon JR; Eacho PI
    Biochem J; 1991 Dec; 280 ( Pt 2)(Pt 2):387-91. PubMed ID: 1747111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential regulation by a peroxisome proliferator of the different multifunctional proteins in guinea pig: cDNA cloning of the guinea pig D-specific multifunctional protein 2.
    Caira F; Clémencet MC; Cherkaoui-Malki M; Dieuaide-Noubhani M; Pacot C; Van Veldhoven PP; Latruffe N
    Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1361-8. PubMed ID: 9494107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective increase in acylation of 1-acylglycerophosphorylcholine in livers of rats and mice by peroxisome proliferators.
    Kawashima Y; Hirose A; Kozuka H
    Biochim Biophys Acta; 1984 Apr; 793(2):232-7. PubMed ID: 6712968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Formation of 8-oxodeoxyguanosine in liver DNA and hepatic injury by peroxisome proliferator clofibrate and perfluorodecanoic acid in rats.
    Kim SC; Hong JT; Jang SJ; Kang WS; Yoo HS; Yun YP
    J Toxicol Sci; 1998 May; 23(2):113-9. PubMed ID: 9644651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ciprofibrate represses alpha 2u-globulin expression in liver and inhibits d-limonene nephrotoxicity.
    Alvares K; Subbarao V; Rao MS; Reddy JK
    Carcinogenesis; 1996 Feb; 17(2):311-6. PubMed ID: 8625456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of rat liver DNA alterations by chronic administration of peroxisome proliferators as detected by 32P-postlabeling.
    Randerath E; Randerath K; Reddy R; Danna TF; Rao MS; Reddy JK
    Mutat Res; 1991 Mar; 247(1):65-76. PubMed ID: 2002806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calcium as a permissive factor but not an initiation factor in DNA synthesis induction in cultured rat hepatocytes by the peroxisome proliferator ciprofibrate.
    Bennett AM; Williams GM
    Biochem Pharmacol; 1993 Dec; 46(12):2219-27. PubMed ID: 8274155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator.
    Rao MS; Subbarao V
    Cancer Lett; 1995 Nov; 97(2):185-8. PubMed ID: 7497461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peroxisome proliferators: species differences in response of primary hepatocyte cultures.
    Elcombe CR; Bell DR; Elias E; Hasmall SC; Plant NJ
    Ann N Y Acad Sci; 1996 Dec; 804():628-35. PubMed ID: 8993577
    [No Abstract]   [Full Text] [Related]  

  • 53. Increased resistance of peroxisome proliferator-induced hepatic lesions to iron overload in rats.
    Rao MS; Subbarao V; Reddy JK
    Cancer Lett; 1986 Jul; 32(1):33-9. PubMed ID: 3742486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peroxisomal enzyme activities in brain and liver of pups of lactating mothers treated with ciprofibrate.
    Singh I; Lazo O
    Neurosci Lett; 1992 Apr; 138(2):283-6. PubMed ID: 1608540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of diethylnitrosamine.
    Glauert HP; Beer D; Rao MS; Schwarz M; Xu YD; Goldsworthy TL; Coloma J; Pitot HC
    Cancer Res; 1986 Sep; 46(9):4601-6. PubMed ID: 2873887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of structurally diverse peroxisome proliferators on rat hepatic sulfotransferase.
    Witzmann F; Coughtrie M; Fultz C; Lipscomb J
    Chem Biol Interact; 1996 Jan; 99(1-3):73-84. PubMed ID: 8620580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
    Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
    Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes.
    Perrone CE; Shao L; Williams GM
    Toxicol Appl Pharmacol; 1998 Jun; 150(2):277-86. PubMed ID: 9653058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of peroxisome proliferation in hepatocytes transplanted into the anterior chamber of the eye. A model system for the evaluation of xenobiotic-induced effects.
    Rao MS; Thorgeirsson S; Reddy MK; Lalwani ND; Evarts RE; Usman MI; Singh B; Reddy JK
    Am J Pathol; 1986 Sep; 124(3):519-27. PubMed ID: 3532814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in the formation of PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration.
    Rodríguez C; Noé V; Cabrero A; Ciudad CJ; Laguna JC
    Mol Pharmacol; 2000 Jul; 58(1):185-93. PubMed ID: 10860941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.